Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole

被引：10

作者：

Alba E. ^{[1
,14
]}

Llombart A. ^{[2
]}

Ribelles N. ^{[1
]}

Ramos M. ^{[3
]}

Fernández R. ^{[4
]}

Mayordomo J.I. ^{[5
]}

Tusquets I. ^{[6
]}

Gil M. ^{[7
]}

Barnadas A. ^{[8
]}

Carabante F. ^{[9
]}

Ruiz M. ^{[10
]}

Vera R. ^{[11
]}

Palomero I. ^{[12
]}

Soriano V. ^{[2
]}

González J. ^{[1
]}

Colomer R. ^{[13
]}

机构：

[1] Hospital Clínico Universitario, Málaga

[2] Instituto Valenciano de Oncología (IVO), Valencia

[3] Centro Oncológico de Galicia, A Coruña

[4] Hospital Cabueñes, Gijón

[5] Hospital Clínico Universitario, Zaragoza

[6] Hospital del Mar, Barcelona

[7] Institut Catalá d'Oncologia, Barcelona

[8] Institut Catalá d'Oncologia (ICO), Badalona

[9] Hospital Carlos Haya, Málaga

[10] Hospital Virgen del Rocío, Sevilla

[11] Hospital de Navarra, Pamplona

[12] Hospital Gregorio Maraìón, Madrid

[13] Institut Catala d'Oncologia (ICO), Girona

[14] Service of Oncology, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Campus Teatinos s/n

来源：

Clinical and Translational Oncology | 2006年 / 8卷 / 3期

关键词：

Basic fibroblastic growth factor; Breast cancer; Endostatin; Letrozole;

D O I：

10.1007/s12094-006-0010-3

中图分类号：

学科分类号：

摘要：

Introduction. To investigate the value of baseline serum levels of VEGF, bFGF, endostatin and their ratio as predictive factors of response to endocrine therapy in patients with metastatic breast cancer (MBC) and positive ER treated with letrozole after tamoxifen failure. Materials and method. The serum levels of endostatin, VEGF and bFGF were determined in post-menopausal patients with progressing MBC from serum samples obtained before initiation of letrozole. The relation between serum angiogenic factor levels and TTP was investigated. Results. Seventy-six patients (45.2%) presented a high endostatin level (>24.6 ng/ml), 40% low bFGF levels (0 pg/ml) and 50.4% low VEGF (≤187 ng/ml). With a median follow-up of 22 months, the median TTP was 12.3 months. Median TTP was worse in patients with high endostatin concentration as well as in the low bFGF group, but was not affected when VEGF was considered. When the two factors were combined, the median TTP of patients with endostatin >24.6 ng/ml and bFGF equal 0 pg/ml was 9.5 months versus 19.5 months in patients with endostatin ≥24.6 ng/ml and bFGF>0 pg/ml. Conclusions. The baseline levels of bFGF and endostatin are predictive factors of efficacy in patients with MBC treated with letrozole and can select groups with different TTP. © FESEO 2006.

引用

页码：193 / 199

页数：6

共 45 条

[1]

Osborne C.K., Tamoxifen in the treatment of breast cancer, N Eng J Med, 339, pp. 1609-1618, (1998)

[2]

Mouridsen H., Gershanovich M., Sun Y., Et al., Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group, J Clin Oncol, 21, pp. 2101-2109, (2003)

[3]

Nabholtz J.M., Bonneterre J., Buzdar A., Robertson J.F., Thurlimann B., Anastrozole (ArimidexTM) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Survival analysis ad updated safety results, Eur J Cancer, 39, pp. 1684-1689, (2003)

[4]

Paridaens R., Dirix L., Lohrisch C., Et al., Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer, Ann Oncol, 14, pp. 1391-1398, (2003)

[5]

Goss P.E., Ingle J.N., Martino S., Et al., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N Engl J Med, 349, pp. 1793-1802, (2003)

[6]

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer, Cancer, 98, pp. 1802-1810, (2003)

[7]

Clark G.M., Prognostic and predictive factors, Diseases of the Breast, pp. 489-514, (2000)

[8]

Yamauchi H., Stearns V., Hayes D.F., When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer, J Clin Oncol, 19, pp. 2334-2356, (2001)

[9]

Folkmann J., The role of angiogenesis in tumor growth, Semin Cancer Biol, 3, pp. 65-71, (1992)

[10]

Poon R.T., Fan S., Wong J., Clinical implications of circulating angiogenic factors in cancer patients, J Clin Oncol, 19, pp. 1207-1225, (2001)

← 1 2 3 4 5 →